

FULL ESTIMATED COST

0.42

0.42

FILE 'MEDLINE' ENTERED AT 15:40:09 ON 18 MAY 2005

FILE 'BIOSIS' ENTERED AT 15:40:09 ON 18 MAY 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'BIOBUSINESS' ENTERED AT 15:40:09 ON 18 MAY 2005

Copyright (c) 1998 The Thomson Corporation.

FILE 'WPIDS' ENTERED AT 15:40:09 ON 18 MAY 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'JICST-EPLUS' ENTERED AT 15:40:09 ON 18 MAY 2005

COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'FSTA' ENTERED AT 15:40:09 ON 18 MAY 2005

COPYRIGHT (C) 2005 International Food Information Service

FILE 'CEABA-VTB' ENTERED AT 15:40:09 ON 18 MAY 2005

COPYRIGHT (c) 2005 DECHEMA eV

FILE 'CEN' ENTERED AT 15:40:09 ON 18 MAY 2005

COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'USPATFULL' ENTERED AT 15:40:09 ON 18 MAY 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:40:09 ON 18 MAY 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 15:40:09 ON 18 MAY 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

=> s NIDD or non-insulin dependent diabetes

L1 82036 NIDD OR NON-INSULIN DEPENDENT DIABETES

=> s somatostatin agonist

L2 1201 SOMATOSTATIN AGONIST

=> s l2 and (decrease body weight)

L3 0 L2 AND (DECREASE BODY WEIGHT)

=> s l2 and (somatostatin type-2 receptor)

10 FILES SEARCHED...

L4 10 L2 AND (SOMATOSTATIN TYPE-2 RECEPTOR)

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 10 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI Specific targeting of camptothecin and combretastatin to tumor cells using
cleavable high affinity **somatostatin agonist** vectors.

ACCESSION NUMBER: 2002:419929 BIOSIS

DOCUMENT NUMBER: PREV200200419929

TITLE: Specific targeting of camptothecin and combretastatin to
tumor cells using cleavable high affinity
somatostatin agonist vectors.

AUTHOR(S): Fuselier, Joseph [Reprint author]; Sun, Lichun [Reprint
author]; Murphy, William A. [Reprint author]; Vasilevitch,
Natalya [Reprint author]; Coy, David H. [Reprint author]

CORPORATE SOURCE: Tulane Health Sciences Center, New Orleans, LA, USA

SOURCE: Proceedings of the American Association for Cancer Research
Annual Meeting, (March, 2002) Vol. 43, pp. 1157. print.
Meeting Info.: 93rd Annual Meeting of the American
Association for Cancer Research. San Francisco, California,
USA. April 06-10, 2002.

ISSN: 0197-016X.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English
ENTRY DATE: Entered STN: 7 Aug 2002
Last Updated on STN: 7 Aug 2002

L4 ANSWER 2 OF 10 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI Treating insulin resistance or Syndrome X by administering somatostatin or
somatostatin agonists.
AN 2003-045722 [04] WPIDS
AB US2002042374 A UPAB: 20030117
NOVELTY - Treating insulin resistance or Syndrome X comprises
administering somatostatin or a **somatostatin agonist**.
ACTIVITY - Antidiabetic; Antilipemic.
MECHANISM OF ACTION - Somatostatin receptor agonist.
In a somatostatin receptor binding assay using human somatostatin
receptor-1 (SSTR-1) to somatostatin receptor-5 (SSTR-5) expressed in
CHO-K1 cells obtained from ATCC (ATCC No.CCL 61), a compound of formula
(Ia) exhibited Ki values (in nm) of 9120, 0.35, 215, 7537 and 11.1 against
SSTR-1-SSTR-5, respectively.
USE - Useful for treating insulin resistance and syndrome X
(claimed). The somatostatin or **somatostatin agonist**
are used for treating diabetes mellitus, hyperinsulinemia and associated
hyperlipidemia.
Dwg.0/0

ACCESSION NUMBER: 2003-045722 [04] WPIDS
DOC. NO. CPI: C2003-011558
TITLE: Treating insulin resistance or Syndrome X by
administering somatostatin or somatostatin agonists.
DERWENT CLASS: B04
INVENTOR(S): CAWTHORNE, M A; LIU, Y; SENNITT, M V
PATENT ASSIGNEE(S): (CAWT-I) CAWTHORNE M A; (LIUY-I) LIU Y; (SENN-I) SENNITT
M V
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002042374	A1	20020411	(200304)*		15

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002042374	A1 Provisional	US 1997-46373P	19970513
		US 1998-76948	19980513

PRIORITY APPLN. INFO: US 1997-46373P 19970513; US
1998-76948 19980513

L4 ANSWER 3 OF 10 USPATFULL on STN
TI Somatostatin-dopamine chimeric analogs
AB Disclosed is a series of somatostatin-dopamine chimeric analogs which
retain both somatostatin and dopamine activity in vivo. An example is:
6-n-propyl-8 β -ergolinglylmethylthioacetyl-D-Phe-c-(Cys-Tyr-D-Trp-Lys-
Abu-Cys)-Thr-NH.sub.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:268255 USPATFULL
TITLE: Somatostatin-dopamine chimeric analogs
INVENTOR(S): Culler, Michael D, Hopkinton, MA, UNITED STATES
Dong, Zheng Xin, Holliston, MA, UNITED STATES
Kim, Sun H, Needham, MA, UNITED STATES
Moreau, Jacques-Pierre, Upton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004209798	A1	20041021

APPLICATION INFO.: US 2004-479771 A1 20040517 (10)
 WO 2002-US17859 20020607
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Leon R Yankwich, Yankwich & Associates, 201 Broadway,
 Cambridge, MA, 02139
 NUMBER OF CLAIMS: 17
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1115
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN
 TI Pharmaceutical compositions which inhibit proliferation of pituitary
 adenomas and method of use thereof
 AB The present invention is directed to a method of reducing the rate of
 proliferation of adenoma cells which method comprises contacting said
 pituitary adenoma cells with one or more of an SSTR1 agonist, and/or one
 or more of an SSTR2 agonist, and/or one or more of SSTR5 agonist, or one
 or more pharmaceutically acceptable salts thereof, either alone or in
 combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:255123 USPATFULL
 TITLE: Pharmaceutical compositions which inhibit proliferation
 of pituitary adenomas and method of use thereof
 INVENTOR(S): Culler, Michael De Witt, Hopkinton, MA, UNITED STATES
 Degli Uberti, Ettore C, Ferrara, ITALY
 Zatelli, Maria C, Ferrara, ITALY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004198653	A1	20041007
APPLICATION INFO.:	US 2004-481066	A1	20040524 (10)
	WO 2002-US19998		20020625

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-300909P	20010625 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Brian Morill, Biomeasure, 27 Maple Street, Milford, MA, 01757	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	740	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN
 TI Somatostatin and somatostatin agonists for treating insulin
 insensitivity and Syndrome X
 AB The present invention relates to a method of treating insulin resistance
 or Syndrome X. The method includes the step of administering a
 therapeutically effective amount of a somatostatin or a
somatostatin agonist to said patient. The invention
 also includes pharmaceutical compositions comprising a somatostatin or
somatostatin agonist and the use of such products in
 the preparation of such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:95280 USPATFULL
 TITLE: Somatostatin and somatostatin agonists for treating
 insulin insensitivity and Syndrome X
 INVENTOR(S): Cawthorne, Michael Anthony, Horsham, UNITED KINGDOM
 Liu, Yong-Ling, Buckingham, UNITED KINGDOM
 Sennitt, Matthew V., Climping, UNITED KINGDOM

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2004072734 A1 20040415
APPLICATION INFO.: US 2003-369143 A1 20030218 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2000-423578, filed on 23 Feb
2000, ABANDONED Continuation of Ser. No. WO
1998-EP3000, filed on 13 May 1998, UNKNOWN Continuation
of Ser. No. US 1997-854943, filed on 13 May 1997,
ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA,
02110
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 1155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN
TI Somatostatin analog and uses thereof
AB Claimed is a **somatostatin agonist** according to
formula (I),

D-Phe-c(Cys-Tyr(I)-D-Trp-Lys-Val-Cys)-Thr-NH.sub.2, (I)

or a pharmaceutically acceptable salt thereof, and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:220203 USPATFULL
TITLE: Somatostatin analog and uses thereof
INVENTOR(S): Gordon, Thomas D., Medway, MA, UNITED STATES
Morgan, Barry A., Franklin, MA, UNITED STATES
Culler, Michael D., Hopkinton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153494	A1	20030814
APPLICATION INFO.:	US 2002-302431	A1	20021121 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336335P	20011121 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	806	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPATFULL on STN
TI METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND OTHER CONDITIONS
AB The present invention relates to a method of treating hyperlipidemia and
to reducing triacylglycerols. glycerol and cholesterol in a patient. The
method includes the step of administering a therapeutically effective
amount of a type-5 selective **somatostatin agonist** to
said patient. A pharmaceutical composition comprises said agonist and
such product is used in the preparation of the composition for use in
treating hyperlipidemia or reducing triacylglycerols, glycerol and
cholesterol in a patient's body.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:273372 USPATFULL
TITLE: METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND
OTHER CONDITIONS
INVENTOR(S): CAWTHORNE, MICHAEL ANTHONY, WEST SUSSEX, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., W. SUSSEX, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151500	A1	20021017
APPLICATION INFO.:	US 2000-423683	A1	20000320 (9)
	WO 1998-EP2998		19980513

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRIAN R MORRILL, BIOMEASURE INC, 27 MAPLE STREET,
MILFORD, MA, 01757-3650

NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 587

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPATFULL on STN
TI METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X
AB The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a **somatostatin agonist** to said patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:78717 USPATFULL
TITLE: METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X
INVENTOR(S): CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002042374	A1	20020411
APPLICATION INFO.:	US 1998-76948	A1	19980513 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46373P	19970513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1115	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 10 USPATFULL on STN
TI Method of treating hyperlipidemia
AB The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective **somatostatin agonist** to the patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:166969 USPATFULL
TITLE: Method of treating hyperlipidemia
INVENTOR(S): Cawthorne, Michael Anthony, Horsham, United Kingdom
Liu, Yong-Ling, Buckingham, United Kingdom
Sennitt, Matthew V., Chipstead, United Kingdom
PATENT ASSIGNEE(S): Biomeasure, Incorporated, Milford, MA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004928		19991221
APPLICATION INFO.:	US 1998-78111		19980513 (9)

NUMBER	DATE

PRIORITY INFORMATION: US 1997-46346P 19970513 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Conway, John D. Fish & Richardson
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULL on STN
TI Method of treating hyperprolactinemia and prolactinomas
AB A method of treating hyperprolactinemia in an animal, including a human, administers one or more somatostatin type-5 receptor agonist(s) to, for example, lower abnormally high levels of prolactin in the blood of the animal. A method of treating a subject, including a human, afflicted by a prolactinoma, administers one or more type-5 receptor selective agonist(s) to, for example, lower prolactin secretion and/or decrease tumor size in the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:132778 USPATFULL
TITLE: Method of treating hyperprolactinemia and prolactinomas
INVENTOR(S): Melmed, Shlomo, Los Angeles, CA, United States
Shimon, Ilan, Beverly Hills, CA, United States
Culler, Michael D., Hopkinton, MA, United States
PATENT ASSIGNEE(S): Cedars-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972893		19991026
APPLICATION INFO.:	US 1997-852221		19970506 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Celsa, Bennett		
LEGAL REPRESENTATIVE:	Pretty, Schroeder & Poplawski		
NUMBER OF CLAIMS:	44		
EXEMPLARY CLAIM:	1		
LINE COUNT:	787		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:38:47 ON 18 MAY 2005)

FILE 'MEDLINE, BIOSIS, BIOBUSINESS, WPIDS, JICST-EPLUS, FSTA, CEABA-VTB, CEN, USPATFULL, DGENE, EMBASE' ENTERED AT 15:40:09 ON 18 MAY 2005

L1 82036 S NIDD OR NON-INSULIN DEPENDENT DIABETES
L2 1201 S SOMATOSTATIN AGONIST
L3 0 S L2 AND (DECREASE BODY WEIGHT)
L4 10 S L2 AND (SOMATOSTATIN TYPE-2 RECEPTOR)

=> s l4 and l1

L5 4 L4 AND L1

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 4 USPATFULL on STN
TI Somatostatin and somatostatin agonists for treating insulin insensitivity and Syndrome X
AB The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a **somatostatin agonist** to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or **somatostatin agonist** and the use of such products in

the preparation of such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:95280 USPATFULL
TITLE: Somatostatin and somatostatin agonists for treating
insulin insensitivity and Syndrome X
INVENTOR(S): Cawthorne, Michael Anthony, Horsham, UNITED KINGDOM
Liu, Yong-Ling, Buckingham, UNITED KINGDOM
Sennitt, Matthew V., Climping, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004072734	A1	20040415
APPLICATION INFO.:	US 2003-369143	A1	20030218 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-423578, filed on 23 Feb 2000, ABANDONED Continuation of Ser. No. WO 1998-EP3000, filed on 13 May 1998, UNKNOWN Continuation of Ser. No. US 1997-854943, filed on 13 May 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1155		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 4 USPATFULL on STN
TI METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND OTHER CONDITIONS
AB The present invention relates to a method of treating hyperlipidemia and
to reducing triacylglycerols. glycerol and cholesterol in a patient. The
method includes the step of administering a therapeutically effective
amount of a type-5 selective **somatostatin agonist** to
said patient. A pharmaceutical composition comprises said agonist and
such product is used in the preparation of the composition for use in
treating hyperlipidemia or reducing triacylglycerols, glycerol and
cholesterol in a patient's body.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:273372 USPATFULL
TITLE: METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND
OTHER CONDITIONS
INVENTOR(S): CAWTHORNE, MICHAEL ANTHONY, WEST SUSSEX, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., W. SUSSEX, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151500	A1	20021017
APPLICATION INFO.:	US 2000-423683	A1	20000320 (9)
	WO 1998-EP2998		19980513
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BRIAN R MORRILL, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 01757-3650		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	587		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 4 USPATFULL on STN
TI METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X
AB The present invention relates to a method of treating insulin resistance
or syndrome X in a patient. The method includes the step of
administering a therapeutically effective amount of a somatostatin or a
somatostatin agonist to said patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:78717 USPATFULL
TITLE: METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X
INVENTOR(S): CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002042374	A1	20020411
APPLICATION INFO.:	US 1998-76948	A1	19980513 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46373P	19970513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1115	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 4 USPATFULL on STN
TI Method of treating hyperlipidemia
AB The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective **somatostatin agonist** to the patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:166969 USPATFULL
TITLE: Method of treating hyperlipidemia
INVENTOR(S): Cawthorne, Michael Anthony, Horsham, United Kingdom
Liu, Yong-Ling, Buckingham, United Kingdom
Sennitt, Matthew V., Chipstead, United Kingdom
PATENT ASSIGNEE(S): Biomeasure, Incorporated, Milford, MA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004928		19991221
APPLICATION INFO.:	US 1998-78111		19980513 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46346P	19970513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Russel, Jeffrey E.	
LEGAL REPRESENTATIVE:	Conway, John D.Fish & Richardson	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	584	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s (H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH)
10 FILES SEARCHED...
L6 4 (H-D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-THR-OH)
=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 4 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI Treating hepatoma in mammals - using octa peptide analogues of somatostatin, used for treating liver cancer.
AN 1993-288120 [36] WPIDS

AB WO 9316718 A UPAB: 19931122
Method comprises administering a compsn. comprising an octapeptide of formula H-Al-Cys-A2-D-Trp-Lys-A3-Cys-A4-Y (I) or their salts or complexes. In (I), A1 = D-beta-Nal or D-Phe; A2 = Phe, pentafluoro-Phe or p-substd. X-Phe where X is halogen, NH2, NO2, OH or 1-3C alkyl; A3 = Thr, Ser, Phe, Val, alpha-aminobutyric acid or Ile; A4 = Thr, beta-Nal or Trp; and Y = NH2 or OH.

Pref. (I) include e.g. H-D-beta-Nal-Cys-Tyr-D -Trp-Lys-Val-Cys-Thr-NH2 (Ia) and H-D-Phe-Cys-Phe-D -Trp-Lys-Thr-Cys-Thr-OH. (I) are pref. prepared by solid phase peptide synthesis.

USE - (I) are somatostatin analogues which inhibit the growth of hepatoma cells and can be used for the treatment of liver cancer.

Dwg.0/0

ABEQ US 5411943 A UPAB: 19950619

Treatment of hepatoma comprises admin of a compsn comprising an octapeptide of formula H-Al-Cys-A2-D-Trp -Lys-A3-Cys-A4-Y. A1= D-beta-Nal or D-Phe. A2= Phe, pentafluoro-Phe or p-substd XPhe. X= halo, NH2, NOS, OH or 1-3C alkyl. A3= Thr, Ser, Phe, Val, alpha-aminobutyric acid or Ile. A4= Thr, beta-Nal or Trp. Y= NH2 or OH.

USE - As somatostatin analogs for the treatment of hepatoma. Dosage is 10-500 mcg/kg/day. Administration may be by liver perfusion, subcutaneous, intraneous, enteral, transdermal or transmucosal.

Dwg.0/1

ACCESSION NUMBER: 1993-288120 [36] WPIDS

DOC. NO. CPI: C1993-128566

TITLE: Treating hepatoma in mammals - using octa peptide analogues of somatostatin, used for treating liver cancer.

DERWENT CLASS: B04

INVENTOR(S): BOGDEN, A E

PATENT ASSIGNEE(S): (BIOM-N) BIOMEASURE INC

COUNTRY COUNT: 20

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9316718	A1	19930902	(199336)*	EN	19
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE					
W: CA JP					
EP 585444	A1	19940309	(199410)	EN	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE					
JP 06507423	W	19940825	(199438)		6
US 5411943	A	19950502	(199523)		7
EP 585444	A4	19960110	(199633)		
EP 585444	B1	20010725	(200143)	EN	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE					
DE 69330483	E	20010830	(200158)		
ES 2160595	T3	20011116	(200201)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9316718	A1	WO 1993-US1679	19930225
EP 585444	A1	EP 1993-907029	19930225
		WO 1993-US1679	19930225
JP 06507423	W	JP 1993-515069	19930225
		WO 1993-US1679	19930225
US 5411943	A	US 1992-840881	19920225
EP 585444	A4	EP 1993-907029	
EP 585444	B1	EP 1993-907029	19930225
		WO 1993-US1679	19930225
	Related to	EP 2001-200266	19930225
DE 69330483	E	DE 1993-630483	19930225
		EP 1993-907029	19930225
		WO 1993-US1679	19930225

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 585444	A1 Based on	WO 9316718
JP 06507423	W Based on	WO 9316718
EP 585444	B1 Based on	WO 9316718
DE 69330483	E Based on	EP 585444
	Based on	WO 9316718
ES 2160595	T3 Based on	EP 585444

PRIORITY APPLN. INFO: US 1992-840881 19920225

L6 ANSWER 2 OF 4 USPATFULL on STN

TI Oligonucleotide conjugates

AB The present invention relates to an oligonucleotide conjugate, comprising: (a) an oligonucleotide at least part of whose sequence is complementary to an intracellular nucleic acid sequence; and (b) a somatostatin analog. The present invention also relates to a medicament containing this oligonucleotide conjugate, preferably for treating tumors in which the somatostatin receptor (SSTR) is overexpressed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:176379 USPATFULL

TITLE: Oligonucleotide conjugates

INVENTOR(S): Eisenhut, Michael, Heidelberg, DE, United States
Mier, Walter, Heidelberg, Germany, Federal Republic of
Eritja, Ramon, Barcelona, Spain
Haberkorn, Uwe, Schwetzingen, Germany, Federal Republic
of

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001029035	A1	20011011
APPLICATION INFO.:	US 2001-781980	A1	20010214 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10006572	20000214
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Dean H. Nakamura, Roylance, Abrams, Berdo & Goodman, L.L.P., Suite 600, 1300 19th Street, N.W., Washington, DC, 20036-2680	

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Page(s)

LINE COUNT: 844

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 4 USPATFULL on STN

TI Inhibition of trauma-induced tumor growth

AB A method for inhibiting in a mammal the accelerated growth of a solid primary or metastatic tumor resulting from tissue trauma caused surgically, non-surgically, or by tissue ulceration, which method comprises the step of administering to the mammal a therapeutically effective amount of somatostatin or a somatostatin agonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:27180 USPATFULL

TITLE: Inhibition of trauma-induced tumor growth

INVENTOR(S): Bogden, Arthur E., Hopedale, MA, United States

Moreau, Jaques-Pierre, Upton, MA, United States

PATENT ASSIGNEE(S): Biomeasure, Inc., Milford, MA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5504069		19960402
APPLICATION INFO.:	US 1993-16720		19930211 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Russel, Jeffrey E.		
LEGAL REPRESENTATIVE:	Fish & Richardson, McGowan, William E.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	917		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 4 USPATFULL on STN
 TI Hepatoma treatment with somatostatin analogs
 AB A method for treating liver cancer in a mammalian subject. The method includes administering to the subject a composition which contains a therapeutically effective amount of an octapeptide of the following formula: ##STR1## wherein, A.sub.1 is D-β-Nal or D-Phe; A.sub.2 is Phe, pentafluoro-Phe, or p-substituted X-Phe where X is a halogen, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl; A.sub.3 is Thr, Ser, Phe, Val, α-aminobutyric acid, or Ile; A.sub.4 is Thr, β-Nal, or Trp; and Y is NH.sub.2 or OH; or a pharmaceutically acceptable salt or complex thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 95:38654 USPATFULL
 TITLE: Hepatoma treatment with somatostatin analogs
 INVENTOR(S): Bogden, Arthur E., Hopedale, MA, United States
 PATENT ASSIGNEE(S): Biomeasure, Inc., Milford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5411943		19950502
APPLICATION INFO.:	US 1992-840881		19920225 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
LEGAL REPRESENTATIVE:	Fish & Richardson		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	465		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e cawthrone/au

E1	2	CAWTHRON P A/AU
E2	2	CAWTHRON R J/AU
E3	0 -->	CAWTHRONE/AU
E4	1	CAWTHRONE C/AU
E5	1	CAWTHRONE C E/AU
E6	3	CAWTHRONE CHRIS E/AU
E7	1	CAWTHRONE J/AU
E8	2	CAWTHRONE M A/AU
E9	1	CAWTLE L/AU
E10	1	CAWTON R M/AU
E11	1	CAWUNDER P/AU
E12	1	CAWVEY J/AU

=> s e8

L7 2 "CAWTHRONE M A"/AU

=> d l7 ti abs ibib tot

L7 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 TI MEASUREMENTS OF LIPID PER OXIDATION AND ALPHA TOCOPHEROL DESTRUCTION

IN-VITRO AND IN-VIVO AND THEIR SIGNIFICANCE IN CONNECTION WITH THE
BIOLOGICAL FUNCTION OF VITAMIN RAT MANY ORGANS MAIZE-M OIL COD LIVER OIL.

ACCESSION NUMBER: 1969:197876 BIOSIS
DOCUMENT NUMBER: PREV196950000866; BA50:866
TITLE: MEASUREMENTS OF LIPID PER OXIDATION AND ALPHA TOCOPHEROL
DESTRUCTION IN-VITRO AND IN-VIVO AND THEIR SIGNIFICANCE IN
CONNECTION WITH THE BIOLOGICAL FUNCTION OF VITAMIN RAT MANY
ORGANS MAIZE-M OIL COD LIVER OIL.
AUTHOR(S): DIPLOCK A T; **CAWTHRONE M A**; MURRELL E A; GREEN J;
BUNYAN J
SOURCE: British Journal of Nutrition, (1968) Vol. 22, No. 3, pp.
465-472.
CODEN: BJNUAV. ISSN: 0007-1145.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: Unavailable

L7 ANSWER 2 OF 2 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

TI Acute regulation of insulin release by the pituitary gland in relation to
hyperinsulinaemia and obesity.
AB The pituitary glands from mice rendered obese by gold thioglucose
treatment and by dietary manipulation, and pituitary glands from lean mice
after a high food intake or a glucose load, were shown to stimulate
insulin secretion from isolated pancreatic islets. The insulin releasing
activity of pituitary glands from obese (ob/ob) mice was reduced by
fasting for 24 and 48 h. Results obtained with pituitary glands from
ob/ob and from lean ob/+ and +/+ mice suggest that the insulin releasing
property manifests a gene dosage effect. Pituitary glands from 3-week-old
(young) ob/ob mice stimulated insulin secretion to the same extent as
pituitary glands from 3-month-old (adult) ob/ob mice. The pancreatic
islets of young ob/ob mice were shown to be somewhat more responsive to
stimulation by the pituitary factor than were lean ob/+ or +/+ islets from
this age group. The concept that high insulin level, partly under
pituitary control, and high caloric intake may be interlinked and may, in
combination, be a major factor in producing obesity is discussed.
Furthermore, it is suggested that the pituitary insulin releasing factor
may play a role in the early development of obesity in the animal models
studied.

ACCESSION NUMBER: 79202366 EMBASE
DOCUMENT NUMBER: 1979202366
TITLE: Acute regulation of insulin release by the pituitary gland
in relation to hyperinsulinaemia and obesity.
AUTHOR: Beloff-Chain A.; Bogdanovic S.; **Cawthorne M.A.**
CORPORATE SOURCE: Dept. Biochem., Imp. Coll. Sci. Technol., London SW7 2BX,
United Kingdom
SOURCE: Journal of Endocrinology, (1979) Vol. 81, No. 3, pp.
271-279.
CODEN: JOENAK
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
003 Endocrinology
023 Nuclear Medicine
LANGUAGE: English

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20040143427 A1

L4: Entry 1 of 2

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040143427

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040143427 A1

TITLE: Method for simulating drilling of roller cone bits and its application to roller cone bit design and performance

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Huang, Sujian	The Woodlands	TX	US	
<u>Cawthorne</u> , Chris E.	The Woodlands	TX	US	

US-CL-CURRENT: 703/10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 2. Document ID: US 20030195733 A1

L4: Entry 2 of 2

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030195733

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030195733 A1

TITLE: Method for simulating drilling of roller cone bits and its application to roller cone bit design and performance

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Huang, Sujian	The Woodland	TX	US	
<u>Cawthorne</u> , Chris E.	The Woodlands	TX	US	

US-CL-CURRENT: 703/10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms

Documents

cawthorne.in.

2

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
cawthron.in.	2

Database:

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

US OCR Full-Text Database

EPO Abstracts Database

JPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

L4

Refine Search

Recall Text



Clear

Interrupt

Search History

DATE: Wednesday, May 18, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set

DB=PGPB; PLUR=YES; OP=OR

<u>L4</u>	cawthron.in.	2	<u>L4</u>
<u>L3</u>	6004928.pn.	0	<u>L3</u>
<u>L2</u>	2003153494	0	<u>L2</u>
<u>L1</u>	2004072734	0	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L6 and L5	0

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L7

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, May 18, 2005 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L7</u>	L6 and L5	0	<u>L7</u>
<u>L6</u>	cawthorne.in.	64	<u>L6</u>
<u>L5</u>	L4 and NIDD	2	<u>L5</u>
<u>L4</u>	L3 and obesity	418	<u>L4</u>
<u>L3</u>	L1 and (somatostatin type-2 receptor agonist)	418	<u>L3</u>
<u>L2</u>	L1 and (decrease body weight)	442	<u>L2</u>
<u>L1</u>	somatostatin and obesity	446	<u>L1</u>

END OF SEARCH HISTORY